Alnylam Pharmaceuticals (ALNY) Retained Earnings (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Retained Earnings came in at -$6.3 billion in Q2 2026, up 14.56% YoY from -$5.5 billion in Q2 2025, and up 2.53% on a QoQ basis from -$6.5 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Retained Earnings (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Retained Earnings data on file, last reported at -$6.3 billion in Q2 2026.
- Quarterly Retained Earnings rose 14.56% year-over-year to -$6.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$6.3 billion (up 14.56% YoY) and the FY2025 annual result came in at -$6.7 billion, up 8.03% from the prior year.
- Retained Earnings climbed to -$6.3 billion in Q2 2026, from -$6.5 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$5.7 billion in Q1 2022 to a low of -$7.4 billion in Q2 2025.
- A 5-year average of -$6.8 billion and a median of -$6.9 billion in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings fell 22.82% — and 2026, when it advanced 14.56%.
- Tracing ALNY's Retained Earnings over 5 years: stood at -$6.6 billion in 2022, then retreated by 6.7% to -$7.0 billion in 2023, then retreated by 3.97% to -$7.3 billion in 2024, then advanced by 8.03% to -$6.7 billion in 2025, then rose by 5.53% to -$6.3 billion in 2026.
- The last three Retained Earnings figures came in at -$6.3 billion (Q2 2026), -$6.5 billion (Q1 2026), and -$6.7 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.33 Bn |
| Mar 31, 2026 | -24.89 Mn |
| Dec 31, 2025 | -6.70 Bn |
| Sep 30, 2025 | -21.78 Mn |
| Jun 30, 2025 | -29.95 Mn |
| Mar 31, 2025 | -7.35 Bn |
| Dec 31, 2024 | -7.29 Bn |
| Sep 30, 2024 | -7.20 Bn |
| Jun 30, 2024 | -34.64 Mn |
| Mar 31, 2024 | -26.99 Mn |
| Dec 31, 2023 | -7.01 Bn |
| Sep 30, 2023 | -32.34 Mn |
| Jun 30, 2023 | -7.02 Bn |
| Mar 31, 2023 | -6.74 Bn |
| Dec 31, 2022 | -44.65 Mn |
| Sep 30, 2022 | -43.78 Mn |
| Jun 30, 2022 | -42.22 Mn |
| Mar 31, 2022 | -5.68 Bn |
| Dec 31, 2021 | -33.26 Mn |
| Sep 30, 2021 | -34.23 Mn |